FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.
about
Clinical Implications of P-Glycoprotein Modulation in Drug-Drug Interactions.Database analyses for the prediction of in vivo drug-drug interactions from in vitro data.Use of in vitro drug metabolism data to evaluate metabolic drug-drug interactions in man: the need for quantitative databases.Role of drug metabolism in drug discovery and development.Dapoxetine, a novel treatment for premature ejaculation, does not have pharmacokinetic interactions with phosphodiesterase-5 inhibitors.In vitro studies in drug discovery and development: an analysis of study objectives and application of good laboratory practices (GLP).In vitro tests for predicting drug-drug interactions: the need for validated procedures.Intestinal drug absorption and bioavailability: beyond involvement of single transport function.Progress towards prediction of human pharmacokinetic parameters from in vitro technologies."Cocktail" approaches and strategies in drug development: valuable tool or flawed science?Drug-drug, drug-dietary supplement, and drug-citrus fruit and other food interactions: what have we learned?The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique.Effect of Moringa oleifera Lam. leaf powder on the pharmacokinetics of nevirapine in HIV-infected adults: a one sequence cross-over studyIn vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate.Risk assessment of drug-drug interactions using hepatocytes suspended in serum during the drug discovery process.Variability in activity of hepatic CYP3A4 in patients infected with HIV.Predicting drug candidate victims of drug-drug interactions, using microdosing.Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein.
P2860
Q30234940-682184DA-2EB8-4468-A623-63EA4F1D241FQ30913359-9FAADBD6-B71E-4F38-8FB6-014A1F6909CCQ31900846-3C83CE9F-288B-4BF0-A60F-8D65B752225AQ34386829-18F140E6-501A-49FB-80DF-8AF5B8F6A3C2Q34562839-6F7E06FA-F524-436D-A964-801F0FB9362FQ35027915-54662BC0-043E-429E-8195-5B72C90A31FEQ35060620-18AC0718-4B0E-4647-9474-6B700D9C5FAAQ35153169-DD9BEDC9-C724-4F2E-B959-560F9775DB7CQ35620660-42A5D255-79A0-44B4-8F03-69851546DFBBQ35640730-3154B035-A1B6-456E-8D5E-456AFBBD828BQ35774851-C5C34B51-0542-42F6-A991-31B20A18DA83Q35846680-548DED13-69CB-440A-AC04-C936D41E7989Q37697972-D3CD2626-3CFF-4E93-B9ED-7B945C576DCDQ43090797-2EC263AC-2B21-4455-877F-9CD7A13C467DQ44795024-558EBE0B-D794-4AEA-8B98-711CD1760260Q44874904-335CB55A-738F-4321-8ECE-C28FB8ADB8CFQ45348533-7815F6C4-FD6E-47DB-88EA-7FB3846929D9Q47695462-9221FC59-F2B9-4527-8573-11959AFC5645
P2860
FDA evaluations using in vitro metabolism to predict and interpret in vivo metabolic drug-drug interactions: impact on labeling.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
FDA evaluations using in vitro ...... eractions: impact on labeling.
@en
FDA evaluations using in vitro ...... eractions: impact on labeling.
@nl
type
label
FDA evaluations using in vitro ...... eractions: impact on labeling.
@en
FDA evaluations using in vitro ...... eractions: impact on labeling.
@nl
prefLabel
FDA evaluations using in vitro ...... eractions: impact on labeling.
@en
FDA evaluations using in vitro ...... eractions: impact on labeling.
@nl
P2093
P2860
P1476
FDA evaluations using in vitro ...... eractions: impact on labeling.
@en
P2093
Gillespie B
Reynolds K
Sahajwalla C
P2860
P304
P356
10.1177/00912709922008515
P577
1999-09-01T00:00:00Z